Evaluation of MGN1703 Maintenance Treatment in Patients With mCRC With Tumor Reduction During Induction Treatment
NCT02077868
·
clinicaltrials.gov ↗
PHASE3
Phase
UNKNOWN
Status
540
Enrollment
INDUSTRY
Sponsor class
Conditions
Metastatic Colorectal Cancer
Interventions
OTHER:
Usual Maintenance
DRUG:
MGN1703 treatment
Sponsor
Mologen AG